Heart failure & cardiomyopathiesResearch article
Cost-Effectiveness of Tirzepatide for the Management of Heart Failure With Preserved Ejection Fraction and Obesity
- Cost-effectiveness analysis (Markov state-transition model)
- 20-year time horizon
- 3% annual discounting
- deterministic and probabilistic sensitivity analyses
- 10,000 Monte Carlo simulations
Authors' conclusion
Tirzepatide seems to be a cost-effective treatment option for patients with HFpEF and obesity in the United States.
Study context
- Population
- Patients with heart failure with preserved ejection fraction (HFpEF) and obesity in the US; model inputs from the SUMMIT trial
- Comparison
- Tirzepatide vs standard care alone
- Outcome
- Incremental cost-effectiveness ratio
- Follow-up
- 20-year time horizon
Main finding
As reported in the abstract
ICER
| Group | Quality-adjusted life years (QALYs) | Total lifetime costs |
|---|---|---|
| Tirzepatide | 7.27 (95% UI: 3.20-13.70) | $131,686 (Q1-Q3: $113,005-$150,445) |
| Standard care | 6.63 (95% UI: 3.69-11.0) | $87,082 (Q1-Q3: $70,866-$105,268) |
- ICER, tirzepatide vs standard care
- $70,297 per QALY gained
Further findings
Total QALYs
| Outcome | Tirzepatide | Standard care |
|---|---|---|
| Total lifetime costs | $131,686 (IQR $113,005-$150,445) | $87,082 (IQR $70,866-$105,268) |
Probabilistic sensitivity analysis
- Tirzepatide cost-effective in simulations
- >50%
- Probability of cost-effectiveness
- 51%
Deterministic sensitivity analysis
- Model most sensitive to mortality rates and health state utilities
Original publication
Cost-Effectiveness of Tirzepatide for the Management of Heart Failure With Preserved Ejection Fraction and Obesity. JACC Heart Fail. Published 20 April 2026. doi:10.1016/j.jchf.2026.103060
Summarised from the published abstract; every number is checked against it